AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Read more about AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES Read more about AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES
AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Read more about AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
41st Annual J.P. Morgan Healthcare Conference Presentation Read more about 41st Annual J.P. Morgan Healthcare Conference Presentation
AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET Read more about AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET
AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Read more about AMGEN TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) Read more about BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND Read more about AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND
AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS Read more about AMGEN TO HOST WEBCAST INVESTOR CALL FOLLOWING ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS
